Future trends in the treatment of rheumatoid arthritis: Cytokine targets

Rheumatology

Volumn 38, Issue SUPPL. 2, 1999, Pages 11-13

  Breedveld, F C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; IL 10; IL 4; IL 6; Infliximab; Monoclonal antibodies; Rheumatoid arthritis; TNF ; Treatment

Indexed keywords

ACUTE PHASE PROTEIN; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; PROSTAGLANDIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

CARTILAGE DEGENERATION; CONFERENCE PAPER; INFLAMMATION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYNOVIOCYTE;

ARTHRITIS, RHEUMATOID; CYTOKINES; FORECASTING; HUMANS; INTERLEUKINS;

EID: 0032742629     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.suppl_1.11     Document Type: Conference Paper

References (21)

1. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-8.
2. Dolhain RJEM, van der Heiden AN, ter Haar NT, Breedveld FC, Milteburg AM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:1961-9.
3. + T cell clones and T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993;150:4754-65.
4. Joosten LAB, Lubberts E, Duren P, Helsen MMA, Jacobs MJM, Goldman, M. Role of interleukin 4 and interleukin 10 in murine collagen induced arthritis. Arthritis Rheum 1997;40:249-60.
5. Bessis N, Boissier MC, Ferrara P, Blankestein T, Fradelini D, Fournier C. Attenuation of collagen induced arthritis in mice by treatment with vector cells engineered to secrete interlukin 13. Eur J Immunol 1996;26:2399-407.
6. Isomäki P, Luukkainen R, Toivanen P, Punnonen J. The presence of interleukin 13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1693-1702.
7. Maini RN, Paulus H, Breedveld FC et al. rHUIL-10 in subjects with active rheumatoid arthritis (RA): a phase I and cytokine response study. Arthritis Rheum 1997; 40(suppl.):S224.
8. Trentham DE, Dynesius-Trentham RA, Orav EJ et al. Effects of oral administration of collagen on RA. Science 1993;261:1727-30.
9. van Laar JM, Miltenburg AMM, Verdonk MJA et al. Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis. J Autoimmun 1993; 6:159.
10. Elliot MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36:1681-90.
11. Elliot MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1104-10.
12. Rankin EC, Choy EH, Kassimos D et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
13. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
14. TM). Arthritis Rheum 1997; 40(suppl.):S126.
15. Maini RN, Breedveld FC, Kalden JR et al. Low dose methotrexate (MTX) suppresses anti-globulin responses and potentiates efficacy of a chimeric monoclonal anti-TNFα antibody (cA2) given repeatedly in rheumatoid arthritis (RA). Arthritis Rheum 1997;40(suppl.):S126.
16. Feldmann M, Elliot MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997;64:283-350.
17. Paleolog EM, Hunt M, Elliot MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
18. Tak PP, Taylor PC, Breedveld FC et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
19. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997;36:643-50.
20. Bresnihan B, Lookabaugh J, Witt K, Musikic P. Treatment with recombinant human interleukin 1 receptor antagonist (rhUL-1ra) in rheumatoid arthritis (RA): results of a randomized double-blind, placebo-controlled multicenter trial. Arthritis Rheum 1996;39(suppl.):S73.
21. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993;20:259-62.